(NASDAQ: CTKB) Cytek Biosciences's forecast annual revenue growth rate of 5.05% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.14%.
Cytek Biosciences's revenue in 2025 is $196,035,000.On average, 7 Wall Street analysts forecast CTKB's revenue for 2025 to be $25,467,655,880, with the lowest CTKB revenue forecast at $24,374,803,627, and the highest CTKB revenue forecast at $26,316,238,479. On average, 7 Wall Street analysts forecast CTKB's revenue for 2026 to be $27,313,672,899, with the lowest CTKB revenue forecast at $25,346,793,291, and the highest CTKB revenue forecast at $28,533,748,930.
In 2027, CTKB is forecast to generate $29,797,081,045 in revenue, with the lowest revenue forecast at $26,769,155,129 and the highest revenue forecast at $32,031,130,587.